Forget Fibrates for Cardiovascular Risk Reduction: Commentary on the Failure and Implications of the PROMINENT Trial | MDedge

Article Type

Changed

Thu, 06/08/2023 - 09:18

Author(s)

Charles P Vega, MD

Pamela R Kushner, MD

In this supplement to Family Medicine, Charles P Vega, MD, and Pamela R Kushner, MD, discuss failure of the PROMINENT trial and implications for use of fibrates to reduce cardiovascular risk.

Publications

MDedge Family Medicine

Family Practice News

Sections

Author(s)

Charles P Vega, MD

Pamela R Kushner, MD

Author(s)

Charles P Vega, MD

Pamela R Kushner, MD

In this supplement to Family Medicine, Charles P Vega, MD, and Pamela R Kushner, MD, discuss failure of the PROMINENT trial and implications for use of fibrates to reduce cardiovascular risk.

In this supplement to Family Medicine, Charles P Vega, MD, and Pamela R Kushner, MD, discuss failure of the PROMINENT trial and implications for use of fibrates to reduce cardiovascular risk.

Publications

MDedge Family Medicine

Family Practice News

Publications

MDedge Family Medicine

Family Practice News

Article Type

Sections

Disallow All Ads

Content Gating

No Gating (article Unlocked/Free)

Alternative CME

Disqus Comments

Default

Eyebrow Default

Information from Industry - Sponsored Supplement

Gate On Date

Wed, 04/12/2023 - 09:30

Un-Gate On Date

Wed, 04/12/2023 - 09:30

Consolidated Pubs: Do Not Show Source Publication Logo

Use ProPublica

CFC Schedule Remove Status

Wed, 04/12/2023 - 09:30

Conference Recap Checkbox

Not Conference Recap

Clinical Edge

Display the Slideshow in this Article

Medscape Article

Display survey writer

Reuters content

Disable Inline Native ads

WebMD Article

Activity Salesforce Deliverable ID

377933.2